WS
TCON

Wedbush Securities’s TRACON Pharmaceuticals, Inc. Common Stock TCON Stock Holding History

Wedbush Securities’s Portfolio TCON Stock Details TCON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,285
Closed -$50K – 1031
2020
Q2 		$50K Buy
+1,285
New +$50.9K ﹤0.01% 904
2019
Q4 		– Sell
-730
Closed -$65K – 1046
2019
Q3 		$65K Buy
730
+492
+207% +$50.5K 0.01% 920
2019
Q2 		$32K Buy
+238
New +$37.6K ﹤0.01% 965

Other funds holding TCON

IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
LA
Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Wedbush Securities's TCON Position: Q3 2020 in Review

Wedbush Securities sold out of TRACON Pharmaceuticals, Inc. Common Stock (TCON) in Q3 2020, closing a stake of 1,285 shares — an estimated $50K sold.

Wedbush Securities first reported a position in TCON in Q2 2019 and held it in 3 quarters. The position peaked at $65K in Q3 2019. 26 funds tracked by Wall St. Rank hold TCON as of Q3 2020.

  • Wedbush Securities reported no remaining TRACON Pharmaceuticals, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • Wedbush Securities sold 1,285 TRACON Pharmaceuticals, Inc. Common Stock shares in Q3 2020, an estimated $50K.
  • Wedbush Securities first reported a position in TRACON Pharmaceuticals, Inc. Common Stock in Q2 2019 and held it in 3 quarters.
  • Wedbush Securities's TRACON Pharmaceuticals, Inc. Common Stock position peaked at $65K in Q3 2019.
  • 26 funds tracked by Wall St. Rank held TRACON Pharmaceuticals, Inc. Common Stock as of Q3 2020.

Based on Wedbush Securities's 13F filing for Q3 2020, filed 20 Oct 2020.